HUVAMER recieves funding from Trond Mohn foundation
Trond Mohn foundation has awarded 18 million NOK to cancer research. The grant is shared between three projects where the project "HUVAMER - Home treatment for Bloodcancer" led by Bjørn Tore Gjertsen was awarded 6 million NOK
By: Tara Helén Steinsland Dowling
Published:
Acute Myeloid Leukaemia (AML) is a rare form of blood cancer with a median age of newly discovered disease at 71 years in Norway. Treatment with intensive chemotherapy prior to bone marrow transplantation to achieve complete remission of the disease is the standard therapy. However, patients unfit to recieve chemotherapy need personalised therapy.
The HUVAMER project aims to develop new combinations of therapeutics to treat AML. The drugs included in the study can be given in tablet form in the patiens home, removing the need for hospitalisation. The saftety and tolerability of the combinations as well as efficacy is to be studied. Additionally the patients will be evaluated for performance status compared to their baseline samples during the study period.
Information about the study
Scientific title: A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients (HUVAMER)
A 1/2 phase multi-center open-label study to investigate treatment of Hydroxyurea in combination with valproic acid or 6-mercaptupurine in combination with valproic acid in patients with AML or high risk MDS unfit for standard therapy.
ARM A: Hydroxyurea + valproic acid
ARM: 6-mercaptopurine + valproic acid